News

Cyclo Therapeutics Inc. Announces Additional Efficacy Data from its Ongoing Phase I/II Trial using Trappsol® CycloTM Intravenously to Treat Patients with Niemann-Pick Disease Type C1 (NPC1)

Cyclo Therapeutics Closes $2.8 Million Private Placement Led by Novit LP with $1.0 Million

GAINESVILLE, FL – (BusinessWire) – August 27, 2020 – Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC) and Alzheimer’s Disease, today announced that it has closed a private placement of its securities with a group of accredited investors...

Digital Annual Family Conference & Interactive Workshop 2020 (REGISTER NOW!)

We are excited to announce that registration for our very first Digital Annual Family Conference & Interactive Workshop on Niemann-Pick Disease, is now open!

Orphazyme completes rolling submission of New Drug Application to U.S. FDA for arimoclomol for Niemann-Pick disease Type C

UK LSD Collaborative: Survey 2020